

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sanai Health Industry Group Company Limited**  
**三愛健康產業集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1889)**

**PROFIT WARNING**

This announcement is made by Sanai Health Industry Group Company Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) in accordance with Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors of the Company (the “**Board**”) would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on the currently available information and the preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2024 (the “**Current Period**”), it is expected that the Group will record a significant decrease in revenue by approximately 40% and decrease in net profit attributable to the owners of the Company to approximately RMB10.0 million for the Current Period as compared with that of approximately RMB15.5 million for the corresponding period of 2023.

The decrease in revenue and net profit attributable to the owners of the Company were mainly attributable to: 1) a decrease in sales volume of pharmaceutical products combined with a decrease in its gross profit margin due to increase in costs of traditional Chinese herbal materials; 2) the absence of interest income from finance leasing business in the Current Period which usually carries almost 100% gross margin; and 3) a significant increase in legal and professional expenses incurred in relation to numerous corporate actions taken in the Current Period including but not limited to, disposal and acquisition of subsidiaries. Such effect was partially offset by net gain on disposal of subsidiaries recorded in the Current Period.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 June 2024. The information disclosed in this announcement only represents a preliminary assessment by the Board based on the information currently available to it, which has not yet been reviewed by the audit committee of the Board. Hence, the interim results of the Group for the six months ended 30 June 2024 may be different from the information disclosed herein.

The Board expects that the announcement on the interim results of the Group for the six months ended 30 June 2024 will be published before the end of August 2024.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Sanai Health Industry Group Company Limited**  
**SHE Hao**  
*Executive Director*

Hong Kong, 28 August 2024

*As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing, Mr. Yuan Chaoyang, Professor Zhang Rongqing, Mr. She Hao and Mr. Xie Haijing, and three independent non- executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.*